SCHEMBL1103929

SCHEMBL1103929

OC1(CCBr)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9467240 0.85 CYP2C19 (0.32)
SCHEMBL31557716 0.81
SCHEMBL2022823 0.69 CYP2C19 (0.31)
SCHEMBL373949 0.69
SCHEMBL131068 0.67
SCHEMBL961666 0.67
SCHEMBL129415 0.67
SCHEMBL1141181 0.67
SCHEMBL17669283 0.67
SCHEMBL373953 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630530-B2 FGFR inhibitor compound and use thereof HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2026-05-19 US disclosed
US-20260085057-A1 SUBSTITUTED INDAZOLES USEFUL FOR TREATMENT AND PREVENTION OF ALLERGIC AND/OR INFLAMMATORY DISEASES IN ANIMALS Bayer Pharma AG (DE) 2026-03-26 US disclosed
US-12559473-B2 Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2026-02-24 US disclosed
US-20260034094-A1 COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS KOJIN THERAPEUTICS INC (US) 2026-02-05 US disclosed
US-12459916-B2 Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2025-11-04 US disclosed
US-12448396-B2 Methods of using heterocyclic compounds as Delta-5 Desaturase inhibitors AMGEN INC. (US) 2025-10-21 US disclosed
EP-4618984-A1 METHODS AND COMPOSITIONS FOR CONTROL OF PAIN AND INFLAMMATION Elanco Animal Health GmbH (DE) 2025-09-24 EP disclosed
EP-4565228-A2 COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS Kojin Therapeutics, Inc. (US) 2025-06-11 EP disclosed
US-20250074890-A1 CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS DANA-FARBER CANCER INSTITUTE, INC. (US) 2025-03-06 US disclosed
US-20250034143-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES, LLC (US) 2025-01-30 US disclosed
US-20090270409-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2009-10-29 US disclosed
US-20090186869-A1 Antiviral compounds GILEAD SCIENCES, INC. (US) 2009-07-23 US disclosed
US-20090186869-A1 Antiviral compounds GILEAD SCIENCES, INC. (US) 2009-07-23 US disclosed
US-20090186869-A1 Antiviral compounds GILEAD SCIENCES, INC. (US) 2009-07-23 US disclosed
WO-2009038974-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2009-03-26 WO disclosed
WO-2009005677-A2 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2009-01-08 WO disclosed
EP-0412110-B1 NOVEL VITAMIN D ANALOGUES LEO PHARM PROD LTD (DK) 1993-07-07 EP disclosed
US-5206229-A Inhibit cell proliferation, antiinflammatory, treating imbalance of immune system LEO PHARMACEUTICAL PRODUCTS LTD (DK) 1993-04-27 US disclosed
EP-0412110-A1 NOVEL VITAMIN D ANALOGUES. LEO PHARM PROD LTD (DK) 1991-02-13 EP disclosed
WO-1989010351-A1 NOVEL VITAMIN D ANALOGUES LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LØVENS KEMIS (DK) 1989-11-02 WO disclosed